Amivantamab: A narrative drug review

Abstract

Epidermal growth factor receptor (EGFR) activating mutations are known oncogenic drivers in non-small-cell lung cancer (NSCLC), with 85% attributable to an exon 19 deletion or exon 21 L858R point substitution. The next most common is an exon 20 insertion mutation (Ex20Ins), which results in an altered active site that sterically interferes with tyrosine kinase inhibitor (TKI) binding, resulting in a poorer response rate to EGFR TKIs. Amivantamab (JNJ-61186372), a fully humanized EGFR- mesenchymal-epithelial transition receptor (MET) bispecific antibody has been approved for use in adults with locally advanced or metastatic NSCLC with EGFR Ex20Ins mutations, whose disease has progressed on or after platinum-based chemotherapy. To prepare this review, we searched various websites, including the European Medicines Agency Drug Manual, United States Food and Drug Administration, PubMed, Science Direct, and UpToDate using the search terms, “Amivantamab,” “NJ-61186372,” “amivantamab-vmjw,” and” “EGFRexon20ins.” We shortlisted 121 articles published between 2015 and 2023, of which 49 were included. This review discusses the clinical indications, adverse effects, safety, pharmacodynamics, pharmacokinetics, and the key research trials that investigated the use of amivantamab.

Keywords

• exon 20ins
• exon 20
• nsclc
• met
• bispecific antibody
• humanized
• jnj-61186372